S. Herschorn

Y. Ung, L. Milot, C. Wong, 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The surgical management of upper tract stone disease among spinal cord-injured patients

A. Garg, S. Shariff, B. Welk, 2013, Spinal Cord.

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial

H. Kölbl, S. Herschorn, T. Rechberger, 2015, Therapeutic advances in urology.

Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial

V. Nitti, S. Herschorn, P. Radziszewski, 2014, International journal of clinical practice.

A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

M. Stölzel, Jeffrey Frankel, S. Herschorn, 2013, Urology.

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

L. Stothers, J. Gajewski, S. Herschorn, 2010, The Journal of urology.

Increasing incidence, but stable mortality, of bladder cancer in Ontario. Analysis of a population sample.

M. Jewett, M. Barkin, S. Herschorn, 1991, Urology.

p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder.

L. Klotz, N. Fleshner, L. Kapusta, 2000, The Journal of urology.

Association between chronic bladder catheterisation and bladder cancer incidence and mortality: a population-based retrospective cohort study in Ontario, Canada

Y. Liu, R. Saskin, S. Narod, 2021, BMJ Open.

Rates of primary and secondary treatments for patients on active surveillance for localized prostate cancer—A population‐based cohort study

R. Saskin, S. Herschorn, G. Kulkarni, 2020, Cancer medicine.

Triamcinolone acetonide injections for the treatment of recalcitrant post-radical prostatectomy vesicourethral anastomotic stenosis: A retrospective look at efficacy and safety.

J. Locke, S. Herschorn, S. Neu, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Effect of radical prostatectomy surgeon volume on complication rates from a large population-based cohort.

R. Saskin, S. Herschorn, G. Kulkarni, 2016, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Could Reduced Fluid Intake Cause the Placebo Effect Seen in Overactive Bladder Clinical Trials? Analysis of a Large Solifenacin Integrated Database.

L. Cardozo, S. Herschorn, C. Chapple, 2017, Urology.

Urodynamic findings 3 months after radiotherapy in patients treated with conformal external beam radiotherapy for prostate carcinoma

C. Danjoux, G. Deboer, S. Herschorn, 2002, BJU international.

Impact of a health education intervention in overactive bladder patients.

S. Herschorn, D. Becker, L. Forte, 2004, The Canadian journal of urology.

Injection Therapy for Urinary Incontinence

S. Herschorn, 2012 .

Chapter 57 – URODYNAMIC EVALUATION OF THE PATIENT WITH PROLAPSE

S. Herschorn, 2008 .

Management of the incontinent patient with a sphincteric stricture following radical prostatectomy

S. Herschorn, Ashley R Cox, Ashley Cox, 2014, Current opinion in urology.

Systemic muscular weakness after botulinum toxin A administration: a review of the literature

J. Locke, S. Herschorn, L. Carr, 2021, Drugs & Therapy Perspectives.

Re: Is There an Association Between Urinary Incontinence and Mortality? A Retrospective Cohort Study.

R. Saskin, S. Herschorn, S. Radomski, 2020, The Journal of urology.

The artificial urinary sphincter for post-radical prostatectomy incontinence: impact on urinary symptoms and quality of life.

N. Fleshner, S. Herschorn, 1996, The Journal of urology.

A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial

W. White, C. Gratzke, S. Herschorn, 2018, Blood pressure monitoring.

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies.

J. Jones, M. Oelke, S. Herschorn, 2010, Urology.

Efficacy and tolerability of tolterodine extended‐release in men with overactive bladder and urgency urinary incontinence

C. Roehrborn, P. Abrams, S. Herschorn, 2006, BJU international.

A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older

M. Oelke, S. Herschorn, F. Haab, 2017, Age and ageing.

Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).

P. Abrams, E. Mueller, C. Gratzke, 2018, European urology.

Cardiovascular Safety of the β3‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial

W. White, C. Gratzke, S. Herschorn, 2018, Journal of clinical pharmacology.

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

C. Schermer, D. Staskin, S. Herschorn, 2018, Health and Quality of Life Outcomes.

Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients

E. Mueller, C. Kelleher, D. Staskin, 2018, Neurourology and urodynamics.

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

C. Schermer, D. Staskin, S. Herschorn, 2017, International Urogynecology Journal.

Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

L. Stothers, J. Gajewski, S. Herschorn, 2011, Current medical research and opinion.

Current status of injectable agents for female stress urinary incontinence.

S. Herschorn, 2001, The Canadian journal of urology.

Mirabegron as Add-on Treatment to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Solifenacin Monotherapy

M. Stölzel, S. Herschorn, Tahir Saleem, 2016 .

Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder.

P. Abrams, W. Artibani, S. Herschorn, 2009, European urology.

Acute urinary retention in men: a comparison of voiding and nonvoiding patients after prostatectomy.

G. Naglie, S. Herschorn, S. Radomski, 1995, The Journal of urology.

Other non‐surgical approaches for the treatment of overactive bladder

S. Herschorn, G. Nadeau, 2015 .

Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis.

R. Saskin, S. Herschorn, G. Kulkarni, 2022, Clinical genitourinary cancer.

Magnetic resonance imaging after intraurethral collagen injected for stress urinary incontinence.

S. Herschorn, L. Carr, C. Leonhardt, 1996, The Journal of urology.

Collagen injections for genuine stress urinary incontinence: Patient selection and durability

S. Herschorn, S. Radomski, 1998, International Urogynecology Journal.

Current use of injectable agents for female stress urinary incontinence.

S. Herschorn, 2005, Reviews in urology.

Urethral Injectables in the Management of SUI and Hypermobility

S. Herschorn, A. Hijaz, 2004 .

Injectables for the Treatment of Female Stress Urinary Incontinence

S. Herschorn, 2003 .

Followup of intraurethral collagen for female stress urinary incontinence.

S. Herschorn, S. Radomski, D. Steele, 1996, The Journal of urology.

Periurethral injection of collagen in the treatment of urinary stress incontinence: ultrasonographic appearance.

S. Herschorn, J. Krysl, A. Arenson, 1995, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

Early experience with intraurethral collagen injections for urinary incontinence.

S. Herschorn, S. Radomski, D. Steele, 1992, The Journal of urology.

Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis

Sender Herschorn, S. Narod, C. Danjoux, 2016, British Medical Journal.

Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men.

K. Coyne, P. Abrams, C. Kelleher, 2008, The journal of sexual medicine.

Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results.

O. Westney, G. Ghoniem, C. Comiter, 2010, The Journal of urology.

Evaluation of Current Biologic Meshes in Pelvic Organ Prolapse Repair

S. Herschorn, Ashley R Cox, Ashley Cox, 2012, Current Urology Reports.

Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study.

S. Herschorn, G. Kulkarni, C. Wallis, 2019, European urology.

Canadian Urological Association best practice report: Diagnosis and management of nocturia.

B. Welk, S. Herschorn, L. Campeau, 2022, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Psoas abscess after operation on lumbar spine.

S. Herschorn, D. Dolfin, A. Arenson, 1983, Urology.

Comprehensive assessment of the morbidity of renal mass biopsy: A population-based assessment of biopsy-related complications.

R. Saskin, S. Herschorn, C. Wallis, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study.

T. Gomes, D. Juurlink, K. Jarvi, 2021, European urology focus.

Patients' perspective of telephone visits during the COVID-19 pandemic.

L. Klotz, J. Locke, S. Herschorn, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Is There an Association Between Urinary Incontinence and Mortality? A Retrospective Cohort Study.

R. Saskin, S. Herschorn, S. Radomski, 2020, The Journal of urology.

New technique for difficult penile implants.

M. Barkin, S. Herschorn, R. Comisarow, 1986, Urology.

OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Activity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology

M. Brin, S. Herschorn, W. Lam, 2013, Advances in Therapy.

NIRS: Past, Present, and Future in Functional Urology

S. Herschorn, A. Koven, 2022, Current Bladder Dysfunction Reports.

DO SYMPTOMS CORRELATE WITH URODYNAMIC FINDINGS FOR MEN WITH POST‐PROSTATECTOMY INCONTINENCE?: MP63‐18

S. Herschorn, J. Labossiere, 2017 .

NIRS: Past, Present, and Future in Functional Urology

S. Herschorn, A. Koven, 2022, Current Bladder Dysfunction Reports.

Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada

R. Saskin, S. Herschorn, S. Radomski, 2019, BMJ Open.

Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study.

S. Narod, P. Cheung, S. Herschorn, 2016, The lancet. Diabetes & endocrinology.

The autologous fascia pubovaginal sling for complicated female stress incontinence.

B. Welk, S. Herschorn, 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence.

J. Collet, J. Gajewski, S. Herschorn, 2005, Urology.

PD20-08 THE EFFECT OF SELECTION AND REFERRAL BIASES FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER WITH SURGERY OR RADIATION

S. Narod, S. Herschorn, G. Morton, 2018 .

Topical minoxidil in the treatment of male erectile dysfunction.

S. Herschorn, S. Radomski, S. Rangaswamy, 1994, The Journal of urology.

Contemporary issues relating to transitional care in bladder exstrophy.

S. Herschorn, A. Lorenzo, D. Keefe, 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*

S. Herschorn, M. Brodsky, J. Heesakkers, 2008, Current medical research and opinion.

The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double‐Blind Phase 3b Trial

S. Herschorn, W. Lam, K. Everaert, 2017, The Journal of urology.

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

N. Campbell, C. Schermer, D. Staskin, 2020, BMC Geriatrics.

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).

S. Kaplan, C. Schermer, K. McVary, 2020, The Journal of urology.

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database

Christopher R. Chapple, Robert Snijder, Linda Cardozo, 2016, Contemporary clinical trials communications.

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER

S. Kaplan, L. Cardozo, T. Crook, 2014, International journal of clinical practice.

Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?

S. Kaplan, S. Herschorn, F. Ntanios, 2014, Urology.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

M. Brin, S. Herschorn, W. Lam, 2011, European urology.

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).

M. Stölzel, S. Herschorn, Tahir Saleem, 2016, European urology.

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).

C. Schermer, D. Staskin, S. Herschorn, 2019, European urology.

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

V. Nitti, S. Herschorn, M. B. Blauwet, 2013, International journal of clinical practice.

Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

V. Nitti, S. Herschorn, N. Martin, 2013, The Journal of urology.

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Xiaohong Yan, R. Dmochowski, C. Nardo, 2013, The Journal of urology.

Mirabegron versus Placebo Add-on Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: a Safety Analysis from the Randomized, Phase 4 PLUS Study.

S. Kaplan, K. McVary, S. Herschorn, 2020, Urology.

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

M. Oelke, V. Nitti, A. Tubaro, 2017, Therapeutic advances in urology.

Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.

V. Nitti, S. Herschorn, M. B. Blauwet, 2015, European urology.

Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder

S. Herschorn, C. Piwko, C. Vicente, 2010, Journal of medical economics.

Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

P. Abrams, E. Mueller, C. Gratzke, 2019, Neurourology and urodynamics.

Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?

L. Cardozo, S. Herschorn, C. Chapple, 2017, International Urogynecology Journal.

Female pelvic floor anatomy: the pelvic floor, supporting structures, and pelvic organs.

Sender Herschorn, S. Herschorn, 2004, Reviews in urology.

Fourth international consultation on incontinence recommendations of the international scientific committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence

C. Dubeau, R. Dmochowski, L. Cardozo, 2010, Neurourology and urodynamics.

Early experience with intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during radical prostatectomy.

L. Klotz, S. Herschorn, 1999, Urology.

Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis.

R. Saskin, C. Danjoux, P. Shah, 2016, European urology.

Urinary undiversion in adults with myelodysplasia: long-term followup.

S. Herschorn, S. Radomski, S. Rangaswamy, 1994, The Journal of urology.

The urologic care of the spinal cord injury patient.

M. Barkin, S. Herschorn, D. Dolfin, 1983, The Journal of urology.

Duloxetine compared with placebo for treating women with symptoms of overactive bladder

W. Steers, K. Kreder, S. Herschorn, 2007, BJU international.

Morbidity and predictors of delayed recognition of iatrogenic ureteric injuries.

J. Locke, S. Herschorn, S. Neu, 2021, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

A population‐based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey

Jacques Corcos, Sender Herschorn, J. Gajewski, 2007, BJU international.

Management of Recurrent Stress Incontinence Following a Sling

S. Herschorn, G. Nadeau, 2014, Current Urology Reports.

Laparoscopic Burch bladder neck suspension: early results.

S. Herschorn, S. Radomski, 1996, The Journal of urology.

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

Xiaohong Yan, R. Dmochowski, V. Nitti, 2013, The Journal of urology.

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder

C. Nardo, V. Nitti, S. Herschorn, 2014, International journal of clinical practice.

Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study.

O. Westney, G. Ghoniem, C. Comiter, 2009, The Journal of urology.

Preoperative Evaluation of Post-prostatectomy Urinary Incontinence: Examining the Evidence for Routine Use of Multichannel Urodynamics

S. Herschorn, J. Labossiere, 2017, Current Bladder Dysfunction Reports.

A retrospective look at term outcomes after definitive surgical repair for traumatic pelvic fracture urethral injuries - does initial management make a difference?

J. Locke, S. Herschorn, S. Neu, 2021, Urology.

The value of immediate or early catheterization of the traumatized posterior urethra.

S. Herschorn, S. Radomski, A. Thijssen, 1992, The Journal of urology.

Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study.

J. Nickel, S. Herschorn, K. Whitmore, 2015, The Journal of urology.

Surgical treatment of stress incontinence in men

P. Abrams, H. Bruschini, R. Kirschner-Hermanns, 2010, Neurourology and urodynamics.

The male sling for post‐prostatectomy urinary incontinence: a review of contemporary sling designs and outcomes

B. Welk, S. Herschorn, 2012, BJU international.

Complications and Interventions in Patients with an Artificial Urinary Sphincter: Long‐Term Results

S. Herschorn, S. Radomski, C. Wallis, 2018 .

Practice patterns of post-radical prostatectomy incontinence surgery in Ontario.

Y. Liu, R. Saskin, L. Klotz, 2014, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Are male slings for post-prostatectomy incontinence a valid option?

B. Welk, S. Herschorn, 2010, Current opinion in urology.

Early experience with small volume periurethral polytetrafluoroethylene for female stress urinary incontinence.

S. Herschorn, A. Glazer, 2000, The Journal of urology.

Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.

D. Murphy, A. Heidenreich, S. Herschorn, 2019, European urology.

Risk Factors Associated with Penile Prosthesi Infection

S. Herschorn, S. Radomski, 1992 .

Autologous muscle derived cells for treatment of stress urinary incontinence in women.

R. Dmochowski, M. Chancellor, S. Herschorn, 2014, The Journal of urology.

Autologous muscle derived cell therapy for stress urinary incontinence: a prospective, dose ranging study.

Sender Herschorn, M. Chancellor, S. Herschorn, 2013, The Journal of urology.

Risk factors associated with penile prosthesis infection.

S. Herschorn, S. Radomski, 1992, The Journal of urology.

Penile prosthesis insertion with corporeal reconstruction with synthetic vascular graft material.

S. Herschorn, R. Ordorica, 1995, The Journal of urology.

187 Multicenter randomized controlled study to evaluate URYX® urethral bulking agent in treating female stress urinary incontinence

S. Herschorn, J. Corcos, S. Radomski, 2004 .

AUTOLOGOUS MUSCLE DERIVED CELLS FOR URINARY SPHINCTER REPAIR FOR RECURRENT OR PERSISTENT STRESS URINARY INCONTINENCE AFTER CONTINENCE SURGERY: PD50‐08

R. Dmochowski, D. Quinlan, M. Chancellor, 2017 .

Urethral injections for female stress incontinence

R. Dmochowski, S. Herschorn, R. Appell, 2006, BJU international.

S-shaped coaxial dilators for male urethral strictures.

S. Herschorn, E. Carrington, 2007, Urology.

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.

L. Cardozo, D. Staskin, S. Herschorn, 2019, European urology.

Evaluation and treatment of blunt renal trauma.

L. Klotz, D. Shoskes, S. Herschorn, 1991, The Journal of urology.

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet

C. Schermer, D. Staskin, S. Herschorn, 2020, Drugs & Aging.

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)

P. Abrams, S. Herschorn, D. Robinson, 2017, BJU international.

Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment.

K. Jünemann, E. Chartier-Kastler, V. Nitti, 2016, The Journal of urology.

Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis

D. Naimark, E. Szumacher, A. Jerath, 2017, MDM policy & practice.

Angiomyolipoma of the kidney extending into the inferior vena cava: sonographic and CT findings.

J. Srigley, S. Herschorn, A. Arenson, 1988, AJR. American journal of roentgenology.

Images - Appendico-vesical fistula.

S. Herschorn, S. Neu, S. Trecarten, 2022, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation

S. Narod, S. Herschorn, G. Morton, 2018, British Journal of Cancer.

Management of high-grade renal traumas with collecting system injuries.

A. Nathens, J. Locke, S. Herschorn, 2021, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Urinary conduit formation using retubularized bowel from continent urinary diversion or intestinal augmentations: I. A multi-institutional experience.

S. Herschorn, M. Ghoneim, N. Bissada, 2004, Urology.

Nephrology and Urology in the Aged Patient

M. F. Michelis, S. Herschorn, D. Oreopoulos, 1993, Developments in Nephrology.

The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction

Tom Marcelissen, Yukio Homma, Vincent Tse, 2019, Neurourology and urodynamics.

PERIURETHRAL COLLECTIONS FOLLOWING HYALURONIC ACID/ DEXTRANOMER (ZUIDEX ®) INJECTION FOR FEMALE STRESS URINARY INCONTINENCE

S. Herschorn, E. Satel, 2008 .

Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

J. Gajewski, L. Valiquette, S. Herschorn, 2011, The Journal of urology.

Female Pelvic Medicine and Reconstructive Pelvic Surgery

N. Diamant, S. Herschorn, H. Drutz, 2003, Springer London.

Fascial slings and bladder neck tapering in the treatment of male neurogenic incontinence.

S. Herschorn, S. Radomski, 1992, The Journal of urology.

The contemporary role of Burch colposuspension

S. Herschorn, Jerome Green, 2005, Current opinion in urology.

Laparoscopic correction of stress urinary incontinence.

S. Herschorn, S. Radomski, 1998, Current opinion in urology.

The autologous fascia pubovaginal sling for complicated female

B. Welk, S. Herschorn, 2013 .

Patent processus vaginalis.

S. Herschorn, P. Vieco, J. Stern, 1990, Clinical nuclear medicine.

Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation.

S. Narod, S. Herschorn, A. Mahar, 2016, Urology.

Hemi-Kock Continent Stoma with Augmentation Enterocystoplasty: Modifications and Outcomes.

J. Locke, S. Herschorn, Humberto R. Vigil, 2021, Urology.

Experience with the hemi-Kock ileocystoplasty with a continent abdominal stoma.

S. Herschorn, S. Radomski, A. Thijssen, 1993, The Journal of urology.

Diagnosis and Management of Kock Afferent Nipple Valve Obstruction.

J. Locke, S. Herschorn, S. Neu, 2021, Urology.

Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy : A Randomised Double-blind Multicentre Phase 3 B Study ( BESIDE )

M. Stölzel, S. Herschorn, C. Chapple, 2016 .

Urodynamic comparison of ileum vs. sigmoid in augmentation cystoplasty for neurogenic bladder dysfunction

S. Herschorn, S. Radomski, A. Stone, 1995, Neurourology and urodynamics.

Calcified ganglioneuroma of the bladder

J. Srigley, S. Herschorn, R. Graham, 1988, Urologic radiology.

Canadian guidelines for the management of benign prostatic hyperplasia.

F. Saad, J. Trachtenberg, M. Elhilali, 2005, The Canadian journal of urology.

Examining lower urinary tract symptom constellations using cluster analysis

L. Matza, C. Thompson, K. Coyne, 2008, BJU international.

SIU/ICUD Consultation on Urethral Strictures: Posterior urethral stenosis after treatment of prostate cancer.

S. Elliott, S. Herschorn, H. Wessells, 2014, Urology.

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

S. Narod, W. Geerts, S. Herschorn, 2017, JAMA.

Multi-Centered Assessment of Clinical Outcomes and Factors Associated With Failure of the Adjustable TransObturator Male System (ATOMS).

J. Locke, S. Herschorn, N. Dwyer, 2020, Urology.

The virtue sling--a new quadratic sling for postprostatectomy incontinence--results of a multinational clinical trial.

V. Nitti, C. Comiter, S. Herschorn, 2014, Urology.

Population based study of long-term rates of surgery for urinary incontinence after radical prostatectomy for prostate cancer.

D. Urbach, R. Saskin, L. Klotz, 2012, The Journal of urology.

Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.

S. Herschorn, J. Nazir, Z. Hakimi, 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

V. Nitti, S. Herschorn, M. B. Blauwet, 2012 .

885 THE EFFICACY AND SAFETY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME – RESULTS FROM A NORTH-AMERICAN PHASE III TRIAL

V. Nitti, S. Herschorn, N. Martin, 2011 .

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.

P. Abrams, S. Herschorn, C. Chapple, 2009, European urology.

Assessment of Secondary Sarcomas Among Patients With Cancer of the Abdomen or Pelvis Who Received Combinations of Surgery, Radiation, and Chemotherapy vs Surgery Alone

R. Saskin, S. Narod, S. Herschorn, 2020, JAMA network open.

Inverted papilloma of the upper urinary tract.

J. Srigley, S. Herschorn, L. Spevack, 1995, The Journal of urology.

Inverted papilloma: An uncommon benign cause of a ureteral filling defect

J. Srigley, S. Herschorn, M. Corkill, 1988, Urologic radiology.

The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer.

S. Narod, S. Herschorn, C. Wallis, 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Pathophysiologic Mechanisms in Postprostatectomy Urinary Incontinence

S. Herschorn, J. Labossiere, 2017 .

Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.

S. Herschorn, M. Drake, S. Macdiarmid, 2017, Urology.

Association Between Primary Local Treatment and Non-prostate Cancer Mortality in Men With Nonmetastatic Prostate Cancer.

A. Seth, S. Herschorn, G. Kulkarni, 2018, Urology.

Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].

M. Stölzel, S. Herschorn, Tahir Saleem, 2016, The Journal of urology.

Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.

S. Herschorn, J. Weiss, E. A. van der Meulen, 2013, The Journal of urology.

Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older-A Population-Based Cohort Study.

T. Gomes, D. Juurlink, M. Mamdani, 2019, JAMA Internal Medicine.

PREVALENCE OF OVERACTIVE BLADDER SYNDROME: EUROPEAN RESULTS FROM THE EPIC STUDY

P. Abrams, C. Kelleher, S. Hunskaar, 2006 .

Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder

D. Ng-Mak, S. Herschorn, A. Degboe, 2014, Current medical research and opinion.

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder

V. Nitti, J. Wyndaele, S. Herschorn, 2014, World Journal of Urology.

Penile implant success in patients with corporal fibrosis using multiple incisions and minimal scar tissue excision.

S. Herschorn, 2000, Urology.

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)

S. Herschorn, C. Chapple, M. Drake, 2017, International journal of clinical practice.

New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men.

L. Klotz, S. Narod, P. Cheung, 2016, European urology.

Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis.

R. Saskin, L. Klotz, S. Narod, 2015, Urology.

Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer

R. Saskin, L. Klotz, S. Narod, 2015, British Journal of Cancer.

Echinococcal disease of the kidney presenting as a renal filling defect.

R. J. Buckley, M. Barkin, S. Herschorn, 1985, The Journal of urology.

Efficacy and Safety of AbobotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Incontinence Performing Regular Clean Intermittent Catheterization: Pooled Results from Two Phase 3 Randomized Studies (CONTENT1 and CONTENT2).

P. Abrams, M. Volteau, P. Denys, 2022, European urology.

Female clear cell adenocarcinoma arising within a urethral diverticulum.

L. Kapusta, S. Herschorn, R. Choo, 2000, The Canadian journal of urology.

Cost-Effectiveness Of Mirabegron 50mg Compared To Tolterodine Er 4mg In The Treatment Of Patients With Overactive Bladder In Canada.

S. Herschorn, J. Nazir, C. Vicente, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Update on management of post-prostatectomy incontinence in 2013.

S. Herschorn, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer.

A. Seth, S. Herschorn, G. Kulkarni, 2018, Urologic oncology.

Effect of Renal Mass Biopsy on Subsequent Nephrectomy Outcomes: A Population-based Assessment.

S. Herschorn, C. Wallis, R. Nam, 2019, European urology.

1340 AUTOLOGOUS MUSCLE DERIVED CELL THERAPY FOR THE TREATMENT OF FEMALE STRESS URINARY INCONTINENCE: A MULTI-CENTER EXPERIENCE

R. Dmochowski, M. Chancellor, S. Herschorn, 2011 .

1524 AUTOLOGOUS MUSCLE-DERIVED CELLS AS THERAPY FOR STRESS URINARY INCONTINENCE: A RANDOMIZED, DOSE-RANGING TRIAL

M. Chancellor, S. Herschorn, C. Birch, 2010 .

Urethrovaginal fistula repair with or without concurrent fascial sling placement: A retrospective review.

J. Locke, S. Herschorn, M. Goldenberg, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Carcinoma in a urethral diverticulum: magnetic resonance imaging and sonographic appearance.

S. Herschorn, J. Murphy, N. Hickey, 2000, Urology.

ORIGINAL RESEARCH—ERECTILE DYSFUNCTION Overactive Bladder Is Associated with Erectile Dysfunction and Reduced Sexual Quality of Life in Men

K. Coyne, P. Abrams, C. Kelleher, 2008 .

Urinary retention after AdVance™ Sling: A multi‐institutional retrospective study

J. Locke, O. Westney, S. Herschorn, 2020, Neurourology and urodynamics.

1959 MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME - RESULTS FROM A NORTH-AMERICAN STUDY

V. Nitti, S. Herschorn, M. B. Blauwet, 2011 .

1958 THE SELECTIVE β3-ADRENORECEPTOR AGONIST MIRABEGRON IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME

V. Nitti, S. Herschorn, N. Martin, 2011 .

The use of Metformin in overactive bladder - a retrospective nested case-control, population-based analysis.

R. Saskin, S. Herschorn, S. Neu, 2023, Urology.

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

M. Oelke, V. Nitti, A. Tubaro, 2017, Therapeutic advances in urology.

New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men.

L. Klotz, S. Narod, P. Cheung, 2016, European urology.

Stress Incontinence Surgery Does Not Cause Pelvic Malignancy: A Population-Based Cohort Study

S. Herschorn, C. Wallis, L. Carr, 2021, The Journal of urology.

M. Stölzel, S. Herschorn, A. Gousse, 2013, Urology.

Surgical management of benign prostatic obstruction: 20-year population-level trends.

R. Saskin, S. Herschorn, C. Wallis, 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

CUAJ – Original Research LaBossiere et al Surgical management of benign prostatic obstruction

R. Saskin, S. Herschorn, C. Wallis, 2020 .

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine

M. Oelke, S. Herschorn, A. Wagg, 2021, Neurourology and urodynamics.